Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 2/20 | 0.45 |
| ▸ | NMT2 | O60551 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433226 | 0.93 | TFPI (0.48) | FURINNMT2NMT1PRSS1TFPI | |
| SCHEMBL29419675 | 0.84 | NMT1 (0.47) | NMT2NMT1 | |
| SCHEMBL31433367 | 0.84 | OPRM1 (0.49) | CTSBOPRM1OPRD1TFPIOPRK1 | |
| SCHEMBL9388801 | 0.83 | FURIN (0.48) | FURINNMT2NMT1PRSS1OPRM1 | |
| SCHEMBL9388806 | 0.83 | FURIN (0.48) | FURINNMT2NMT1PRSS1OPRM1 | |
| SCHEMBL31433335 | 0.83 | IL23R (0.48) | — | |
| SCHEMBL31433466 | 0.83 | NPBWR1 (0.51) | OPRM1OPRD1TFPIOPRK1 | |
| SCHEMBL30753565 | 0.83 | NMT1 (0.54) | NMT2NMT1 | |
| SCHEMBL30973979 | 0.82 | NMT1 (0.47) | FURINNMT2NMT1OPRM1OPRD1 | |
| SCHEMBL30636808 | 0.82 | NMT1 (0.53) | FURINNMT2NMT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | FURIN 1283/4885NMT2 1434/4885NMT1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.